Trial · NCT04625725
Results by group35
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 35
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness | AZD7442 | Primary Analysis | 8 | Participants | |
| Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness | Placebo | Primary Analysis | 17 | Participants | |
| Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness | AZD7442 | Final Analysis | 12 | Participants | |
| Number of Participants With First Case of SARS-CoV-2 RT-PCR-positive Symptomatic Illness | Placebo | Final Analysis | 34 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | AZD7442 | Adverse Events | 1221 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | Placebo | Adverse Events | 593 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | AZD7442 | Serious Adverse Events | 50 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | Placebo | Serious Adverse Events | 23 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | AZD7442 | Medically Attended Adverse Events | 360 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | Placebo | Medically Attended Adverse Events | 157 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | AZD7442 | Adverse Events of Special Interest | 93 | Participants | |
| AEs, SAEs, MAAEs, and AESIs Post Dose of IMP at Time of Primary Efficacy Analysis | Placebo | Adverse Events of Special Interest | 37 | Participants | |
| The Incidence of Participants Who Have a Post-treatment Response (Negative at Baseline to Positive at Any Time Post-baseline) for SARS-CoV-2 Nucleocapsid Antibodies. | AZD7442 | 198 | Participants | ||
| The Incidence of Participants Who Have a Post-treatment Response (Negative at Baseline to Positive at Any Time Post-baseline) for SARS-CoV-2 Nucleocapsid Antibodies. | Placebo | 139 | Participants | ||
| The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP | AZD7442 | 2 | Participants | ||
| The Incidence of SARS-CoV-2 RT-PCR-positive Severe or Critical Symptomatic Illness Occurring After Dosing With IMP | Placebo | 11 | Participants | ||
| The Incidence of COVID-19-related Emergency Department Visits Occurring After Dosing With IMP | AZD7442 | 8 | Participants | ||
| The Incidence of COVID-19-related Emergency Department Visits Occurring After Dosing With IMP | Placebo | 8 | Participants | ||
| Serum AZD7442 Concentrations, PK Parameters if Data Permit. | AZD7442 | Day 8 | 18.667 | Geometric Coefficient of Variation 92.947 | µg/mL |
| Serum AZD7442 Concentrations, PK Parameters if Data Permit. | AZD7442 | Day 29 | 22.602 | Geometric Coefficient of Variation 64.691 | µg/mL |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04625725/results